Subscribe to Newsletter

Retina

Subspecialties Business and Innovation

Sustaining Innovation

| Michael O’Rourke

Sustained-release drug delivery technologies over time, and how future innovators should proceed…
Subspecialties Retina

Jury’s Out

| David A. Eichenbaum

Placing the HAWK/HARRIER data in the wider context of nAMD anti-VEGF trial data.
Subspecialties Retina

A Whole New World

| Jesse Berry

It shouldn't be about epi-on or epi-off CXL… The focus should be on what's best for patients.
Subspecialties Retina

Quite a Stretch

| Mark Hillen

Can brolucizumab extend the AMD anti-VEGF treatment interval?
Subspecialties Retina

Red Light Means Go?

| Ruth Steer

A recent trial shows promise for a new ocular melanoma therapeutic.
Subspecialties Retina

How Low Can You Go?

| Ruth Steer

Optimizing ROP treatment by scaling back the dose.
Subspecialties Retina

A New Dry AMD Target?

| Ruth Steer

A US research team have identified a novel enzyme that appears to play a role in disease progression.
Subspecialties Retina

Retinal Imaging: The Big Picture

| Sponsored by Optos

Highlights from the Optos satellite meeting held at the 17th EURETINA Congress, Barcelona.
Subspecialties Retina

Keep On Keeping On

| Peter Kaiser

The future of retinal drug delivery for the treatment of neovascular disease.
Subspecialties Basic & Translational Research

Image of the Month

An excerpt from the "Science of Sight" exhibition.
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

July Issue of The Ophthalmologist
Disclaimer element

This new disclaimer element is now part of all brands. It is editable on the start page and will be shown on all pages

Once confirmed we store a cookie to not show the disclaimer again.